Please: Login/Register

The Latest Edition of "Eyes on malaria" magazine will be out very soon!! | CALL FOR ARTICLES: AMMREN is inviting journalists / writers / scientists interested in reporting on malaria to send articles for publication in its international magazine “Eyes on Malaria” and for posting on its website. Please contact the AMMREN Secretariat for more details click here. Enjoy your stay!. Volunteers and interns urgently needed to work with an NGO working in the area of malaria and health. Apply through - / Journalists interested in reporting on and writing articles on health issues should please reply through this email:




    Mosquitoes around the home can be reduced significantly by minimizing the amount of standing water available for mosquito breeding. Residents are urged to reduce standing water around the home in a variety of ways.


    The best way is to avoid being bitten by mosquitoes.This can be accomplished using personal protecting  while outdoors when mosquitoes are present. Treated bed nets should be used sleeping. Mosquito repellent should be used when outdoor.


    Nearly half of the world’s population is at risk of getting malaria. Pregnant women are particularly at risk of malaria. Children under 5 years are at high risk of malaria.


  • First Edition

  • Second Edition

  • Third Edition

  • Fourth Edition

  • Fifth Edition

  • Sixth Edition

  • Seventh Edition

  • Eighth Edition

  • Ninth Edition

  • Special Edition

  • INESS Edition

  • Tenth Edition

  • INDEPTH Edition

  • Eleventh Edition

  • Twelfth Edition

  • Special Edition

  • Special Edition

  • Volume 1


Ifakara Health Institute, Bagamoyo, Tanzania

Having done a brilliant job on the Phase 2 testing of the safety & efficacy of GSK Biological’s RTSS malaria vaccine, the Ifakara Health Institute (IHI) became one of the first centres in Africa to launch international Phase 3 trials of RTSS at Bagamoyo in 2009.

The Bagamoyo Research and Training Centre (BRTC) a branch of the IHI is located about 70 kilometers north of Dar-es- salaam and situated within the Bagamoyo District Hospital compound.

           Dr. Salim Abdulla,
        site leader, Bagamoyo

Malaria Clinical Trial Alliance (MCTA) has supported the site in several including infrastructure development, Personnel capacity building and general logistical support.

As the Director Dr. Salim Abdulla explains, the laboratory space created by MCTA has enabled the site to engage other partners to put in resources for vital equipments. He said following a level 3 lab set up in 2010 the site has already won two grants to establish more research in Bagamoyo.  He said this to a visiting MCTA delegation led by Dr Bernhards Ogutu, Senior Clinical trialist.


                    Dr Ogutu and Dr Salim Adbulla at a new facility at BRTC

Dr Salim Abdulla said MCTA financed the construction of the main site building which houses the administration, office space for scientists, conference room, Data room and Laboratory. With this building BRTC now has adequate office space for both administrative functions and office space for scientist, data unit and a spacious laboratory.

Extension of the out- patients department of the Reproductive and Child Health Clinic (RCH) at BDH was partly financed by MCTA, to create enough space for a waiting area, registration area, consulting rooms, vaccination room and a small laboratory.

MCTA financed renovations in two dispensaries and construction of one dispensary. The additional spaces in two dispensaries and the constructed dispensary facilitated recruitment and follow up during the previous and the ongoing trials.

As the Phase lll of RTS,S malaria vaccine trials required a digital X-ray at the site, MCTA financed the refurbishment of the X-ray room at BDH as well as provided the ultramodern equipment both for trials and routine clinics.

 On the future prospects of the IHI, Dr Salim said the centre in Bagamoyo is positioning  itself to take full advantage of the infrastructural to get on board future research into a stronger malaria vaccine against malaria.

The difference Made By MCTA

By Drs Martha Lemnge, & John Lusingu 

Korogwe site is under National Institute for Medical Research NIMR in Tanga. It is one of the two sites in Tanzania participating in phase 3 RTS,S vaccine trial. The site has 9 vaccination centers located some few kilometers from Korogwe district hospital where the main NIMR RTS,S research lab is located.

All these were refurbished between 2006 and 2010 with funds from the Malaria Clinical Trials Alliance (MCTA).

Support from the MCTA thus spans a 5 year period that has seen Korogwe participate in different phases of RTS,S malaria vaccine trials; beginning with a phase II trial known as Mal-049 that was run between Kilifi and Korogwe and then the ongoing phase 3 trial (Mal-055) happening at 11 sites in Africa. Korogwe, like the other sites has received numerous specialized equipment for the lab and hospital that are linked to the RTS,S trial.

       Dr Martha Lemnge,
         Centre Leader

The contribution of the MCTA towards capacity building at Korogwe is significant in terms of the both infrastructure and human development.

With financial support from MCTA we have been able to excel in many ways, helping the communities within the Korogwe catchment area where our vaccine trials have been conducted.

                                                   Continue reading.......

Sixth Edition